Gubra is a Danish biotech company specializing in preclinical drug discovery and research within metabolic and fibrotic diseases, including obesity, diabetes, and NASH. Founded in 2008, the company combines advanced computational modeling, imaging, and lab-based studies to develop innovative therapies. Gubra partners with global pharmaceutical companies and also pursues its own pipeline of drug candidates, including novel peptide-based treatments.